Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02537288
Recruitment Status : Completed
First Posted : September 1, 2015
Last Update Posted : January 6, 2016
Sponsor:
Information provided by (Responsible Party):
Vantia Ltd

Brief Summary:
The purpose of this study is to assess the electrocardiogram (ECG) effects of fedovapagon dose administration relative to placebo in healthy adult male and female subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Fedovapagon Drug: Moxifloxacin Drug: Placebo (for fedovapagon) Phase 1

Detailed Description:

Regulatory guidance (ICH E14) has emphasized the need to obtain clear robust data on the effect of new chemical entities on ECG parameters with focus on cardiac repolarization as measured by the QTc duration. Though many Phase 1, 2 and 3 trials may be conducted they usually have insufficient sample size, infrequent sampling of ECG data, or the use of inadequate controls to overcome the high rate of spontaneous change in QTc duration. This has resulted in regulatory guidance recommending a dedicated or thorough trial to define the ECG effects of new drugs.

This study will be conducted in healthy volunteers to eliminate variables known to have an effect on ECG parameters (concomitant drugs, diseases, etc.). A supra-therapeutic dose of fedovapagon is required to mimic the exposure in healthy volunteers that may occur in the target population under the worst of circumstances (e.g., concomitant use of CYP3A4 inhibitor, concomitant liver disease, presence of heart disease, taking more than the clinical dose prescribed, etc.) and to allow for PK to QTc modeling to assess the effect of drug concentration on cardiac repolarization.

A cross-over trial is the preferred design as subjects act as their own controls and since there is no accumulation of any clinical relevance and the plasma concentration of parent dissipates before 24 hours, a single dose trial will be employed. During the course of the study each subject will be administered fedovapagon at both a clinical and supra-therapeutic dose, placebo and moxifloxacin (as a positive control).

The sample size is driven by the need to do a time-matched statistical analysis on the primary endpoint as per ICH E14 guidance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I Single Centre, Randomized, Double Blind (Except For Moxifloxacin), Placebo And Active Controlled, Four Way Cross Over Study Investigating The Effect Of Single Therapeutic And Supra Therapeutic Doses Of Fedovapagon On The QT/QTC Interval In Healthy Volunteers Using Oral Moxifloxacin To Confirm Assay Sensitivity
Study Start Date : October 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Placebo matched to fedovapagon
One dose of placebo (matched to fedovapagon)
Drug: Placebo (for fedovapagon)
Experimental: Fedovapagon 2 mg
One dose of 2 mg fedovapagon
Drug: Fedovapagon
Experimental: Fedovapagon 20 mg
One dose of 20 mg fedovapagon
Drug: Fedovapagon
Experimental: Moxifloxacin 400 mg (open label)
One dose of moxifloxacin 400 mg (open label)
Drug: Moxifloxacin



Primary Outcome Measures :
  1. Time-matched change from baseline in QTc, placebo-adjusted and corrected for heart rate [ Time Frame: 0-48 hours ]

Secondary Outcome Measures :
  1. Heart rate [ Time Frame: 0-48 hours ]
  2. PR interval [ Time Frame: 0-48 hours ]
  3. QRS interval [ Time Frame: 0-48 hours ]
  4. Uncorrected QT interval [ Time Frame: 0-48 hours ]
  5. ECG morphology especially on repolarization [ Time Frame: 0-48 hours ]
  6. Correlation between the QTc change from baseline and plasma concentrations of fedovapagon [ Time Frame: 0-48 hours ]
  7. Number and type of adverse events [ Time Frame: 0-48 hours ]
  8. The observed maximum plasma concentration (Cmax) [ Time Frame: 0-48 hours ]
  9. Time to reach maximum plasma concentration (tmax) [ Time Frame: 0-48 hours ]
  10. Apparent terminal half-life (t½) [ Time Frame: 0-48 hours ]
  11. Area under the plasma concentration-time curve (AUC0-t), (AUC0-24h) and (AUC0-∞) [ Time Frame: 0-48 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provide signed and dated informed consent before any study-specific procedures are conducted.
  • Healthy males and females 18 to 55 years of age (inclusive).
  • No clinically significant abnormal physical findings.
  • No clinically significant abnormal values for hematology, clinical chemistry or urinalysis at screening or admission.
  • Have a body mass index (BMI) ≥18.0 to ≤29.9 kg/m2 (weight: ≥50 kg and ≤100 kg) at the Screening visit.
  • Be judged by the Investigator to be in good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed at the Screening visit and before the first administration of fedovapagon, moxifloxacin or placebo.
  • Have no clinically significant abnormality on an ECG performed at the Screening visit and on admission to the study center.
  • Have a normal resting blood pressure.
  • Must be able to understand and be willing to comply with study procedures, restrictions and requirements.
  • Agree to refrain from the consumption of grapefruit or grapefruit juice beginning 1 week prior to administration of the initial administration fedovapagon, moxifloxacin or placebo, throughout the trial.
  • Agree to refrain from the consumption of alcohol and/or methylxanthines e.g., caffeine (coffee, tea and cola) beginning 96 hours prior to administration of the initial administration of fedovapagon, moxifloxacin or placebo, throughout the trial.
  • Current non-smokers who have not used any nicotine-containing products (chewed or smoked) or replacement products including electronic cigarettes in the 45 days prior to screening.
  • Woman of child-bearing potential must be using effective methods (failure rate <1%) of birth control at least 4 weeks prior to Screening until 4 weeks after the administration of fedovapagon, moxifloxacin or placebo.
  • Male subjects should be willing to use a condom with spermicide during sexual activity with female partners of child-bearing potential and must not donate sperm. Female sexual partners of male subjects should be willing to avoid pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02537288


Locations
Layout table for location information
Germany
PAREXEL Early Phase Clinical Unit Berlin
Berlin, Germany, 14050
Sponsors and Collaborators
Vantia Ltd
Investigators
Layout table for investigator information
Principal Investigator: Georg Golor, PD Dr med Parexel
Layout table for additonal information
Responsible Party: Vantia Ltd
ClinicalTrials.gov Identifier: NCT02537288    
Other Study ID Numbers: 483-012
First Posted: September 1, 2015    Key Record Dates
Last Update Posted: January 6, 2016
Last Verified: January 2016
Keywords provided by Vantia Ltd:
VA106483
fedovapagon
males
females
moxifloxacin
TQT
QT/QTC
ECG
Nocturia
Additional relevant MeSH terms:
Layout table for MeSH terms
Moxifloxacin
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents